

#### ANZSNM 2022 ASM Program

## FRIDAY 13 May 2022

### Pre-Conference Symposium

Queensland Art Gallery | Gallery of Modern Art (GOMA)

Preclinical Development to Patient Perspectives: The Continued Evolution of Nuclear Medicine

Proudly Sponsored By:

09:00 | Welcome, Danielle Meyrick, Telix Pharmaceuticals

### Session 1: Chair: Melissa Latter

- 09:15 | Pre-Clinical Can we improve imaging and radio-ligand therapies using adjuvants? A/Prof Dr Fiona Simpson, The University of Queensland
- 09:40 | Pre-Clinical Towards clinical evaluation of a new agent for PET imaging of ovarian and pancreatic cancer Professor John Hooper, The University of Queensland
- 10:05 | Outcomes Nuclear Imaging in Cardiac Amyloidosis Dariusz Korczyk
- 10:30 | Morning Tea

#### Session 2: Chair: Loren Katchel

- 11:00 | Clinical Back to the future: thyroid cancer theranostics A/Prof Dr David Pattison, Royal Brisbane and Women's Hospital
- 11:25 | Clinical Emerging technologies: challenges and rewards from a private perspective A/Prof Dr David Wong, I-MED Radiology Network
- 11:50 | Outcomes PET imaging for brain tumours A/Prof Dr Mark Pinkham, ICON Cancer Care and Princess Alexandra Hospital
- 12:15 | Lunch

#### Session 3: Chair: Claire Cuscaden

- 13:00 | Clinical Bridging the gap between diagnosis and treatment of head and neck malignancy what do the referring clinicians need to know? Dr John Blazak, Queensland Health
- 13:25 | Patient A Journey: From Diagnosis to the Nuclear Option Andrew van Nooten
- 13:45 | Telix Presentation Theranostics Applications in Prostate Cancer: Looking beyond Lu-177 PSMA Dr Aviral Singh, GenesisCare
- 14:15 | Conclusion, Danielle Meyrick, Telix Pharmaceuticals
- 14:30 |1 Hour Self-Guided AP10 Gallery / Exhibition Tour Level 3

## ANZSNM ASM 2022

Brisbane Exhibition and Convention Centre Plaza Level, Grey Street Entrance

15:00 - 18:00 | Speaker Support - Concord Speaker Prep 15:00 - 18:00 | Registration - Plaza Ballroom Foyer 17:00 - 18:30 Welcome Reception - Brisbane Convention & Exhibition Centre, Plaza Ballroom 19:00 for 19:30 | AANMS Fellows' Dinner - Watermall at the Queensland Art Gallery

SAT	ruf	RDA'	Y 14 May 2022															
07:00	Cor	ncurre	nt Breakfast Sessions															
Oncobeta Breakfast Session					IS Brea	kfast S	ession				reakfast Session	Cyc	lotek	Breakf	ast Session			
					GN	1S		GORUS						CYCLOTEK				
Early Australian Experience with Rhenium-SCT A/Prof Sid Baxi, Radiation Oncologist, GenesisCare Mrs Rosanne Robinson, General Manager Business Development, ANSTO					iopharn	naceuti	Autoinjector: From Radiopharmaceutical Production to cal Injection , Comece	MIM Software – Advanced solutions for SPECT, PET & Theranostics James Buteau, Peter MacCallum Kathy Willowson, Royal North Shore Hospital					A discovery and update on Cyclotek radiopharmaceuticals and research Dr. Rob Ware					
Plaza	P6			Pla	za P7			Pla	za P8			Pla	ta P9					
07:30 07:30	) - 16 )   Re	:30   S egistra	on and Poster Displays Open - Plaza Ballroom & F Speaker Support - Concord Speaker Prep Room Ition - Plaza Ballroom Foyer RY - Plaza Auditorium	oyer														
08:30 08:50 Chair <b>A Bri</b> j Dr. A	)   W )   Pl : Dr S ght F ndrei	elcom enary Stanley uture	ne & Official Opening 1: y Ngai for Nuclear Medicine - Theragnostics and Beyon u, Stanford University Medical Center, San Francis				Proudly Sponsored By:											
Chair <b>Probi</b> Dr Mi	: Mel i <b>ng w</b> ichell	le Jam		т			Proudly Sponsored By:	Ö										
		-	Concurrent Sessions 1A - 1D															
			ists' Symposium 1	<b>1</b> B	Radio	phar	maceutical Sciences Symposium 1	10	Phys	ics Sy	nposium 1	1D	AAN	IMS F	Registrars' Research Award*			
	<ul> <li>RADPHARM Technologist Presentation Award *</li> <li>Chair: Karen Jones and Remi Hillery</li> </ul>						d* o Pascali and Margaret Aulesbrook	Chair: Daniel Badger and Deborah Carrick						Chair: Dr Joshua Morigi and Dr Eva Wegner				
Paper			Plaza Auditorium	Paper			Plaza P6	Paper			Plaza P7	Paper			Plaza P8			
41	01		'F' Marks the Spot – The Role of 18F- Fluoroethyl-L-tyrosine (18F-FET) and 18 F- Fluorodeoxyglucose (18F-FDG) in the Diagnosis & Biopsy of Brain Tumours., Laetitia Mai, Monash Health *	94	07	10:45	Conjugation and radiolabelling of [225Ac]Ac- macropa-tzPEG3Sq-ch806, a tumour-specific anti-EGFR antibody, and preclinical evaluation in a murine glioma model, Christian Wichmann, Olivia Newton-John Cancer	26	013	10:45	Proudly Sponsored By: CANON MEDICAL Preliminary Assessment of the Impact of Somatostatin Analogues on [68Ga]DOTA- Octreotate Biodistribution, Dale Bailey, Royal North Shore Hospital	7	019	10:45	Empiric radioiodine for hyperthyroidism: outcomes, prescribing patterns and its place in the modern era of theranostics, Emma Boehm, Royal Melbourne Hospital *			
11	02		In111 Platelet Scintigraphy for Immune Thrombocytopaenia, Rosemary Dallen, Sir Charles Gairdner Hospital *	104	08	11:00	Research Institute * From Preclinical to Fit-For-Use in Humans: Manufacture of [18F]DPA-714 at the CAI,Damion Stimson, The University Of Queensland *	72	014	11:00	National Diagnostic Reference Level Nuclear Medicine Survey 2021-22 , Toby Beveridge, Arpansa	85	020	11:00	Comparison of FDG PET to beta-amyloid (Ab) PET in persons with mild cognitive impairment or mild dementia, Kerry Jewell, Austin Health *			
14	03		Avoiding a Total Eclipse of the Heart: Unlocking the True Potential of PET/MRI- Diagnosing Cardiac Sarcoidosis, James Turner, Princess Alexandra Hospital, Queensland Health *	43	09	11:15	In vitro and in vivo characterization of 892r- labeled anti-VISTA antibody CI-8993, Ingrid Burvenich, Olivia Newton-John Cancer Research Institute *	93	015	11:15	Modelling the effects of cascade gamma scatter in PET, Graeme O'keefe, Austin Health	37	021	11:15	Evaluation of the value of pre-operative PET imaging with 68Ga DOTATATE and 18F FDG to differentiate between typical and atypical pulmonary carcinoid tumours using surgical histopathology as the gold standard., Stella Jo, Royal Adelaide Hospital *			
40	04		(VIRTUAL) 68Gallium-PSMA Imaging and Halo Artefacts, Bradley Hancock, Mater Imaging	148	010	11:30	Site Development and Production of a PET radiopharmaceutical for Cholinergic Imaging in a Clinical Research Trial, Melissa Latter, QLD Health *	102	016	11:30	Site Experience of Gamma-ray Imaging with CORIS360* in a Nuclear Medicine Department, Sylvia Gong, Austin Health	125	022	11:30	Prevalence of accessory thyroid tissue detected using 1311odine SPECT/CT imaging: a single- centre experience, Owen Kang, Concord Repatriation General Hospital *			
20	05		(LIVE ZOOM) Battle of the Hearts: An Appropriate Utilisation of Imaging in Heart Failure, Pru Burns, Capital & Coast Dhb *	32	011	11:45	New 18F and 68Ga tracers for PET myocardial perfusion imaging, Joseph loppolo, Sir Charles Gairdner Hospital *	103	017	11:45	3D printed displacement phantom insert to provide contiguous radioactivity concentration change., Matthew Griffiths, Ph.D, Nuclear Medicine Royal Brisbane And Women's Hopsital	149	023	11:45	Diagnostic and staging impact of F18 PSMA- 1007 PET/CT compared with Ga68 PSMA-11 PET/CT in primary staging and assessment of biochemical relapse of prostate cancer, Zahra Sabahi Mohammadi, Liverpool Hospital *			
19	06		Optic Nerve Sheath Meningioma: A Case Study, Mikayla Dimitri, SA Medical Imaging, Royal Adelaide Hospital, Department of Nuclear Medicine, PET & Bone Densitometry *	79	012	12:00	Improving PET Radiopharmaceutical Yields: From Cyclotron to Synthesis Module , Soren Lummis, Q-TRaCE, Royal Brisbane & Women's Hospital *	119	018	12:00	Centiloid harmonisation across PET cameras without using paired data, Shenpeng Li, CSIRO	105	024	12:00	Stage IV Non Small Cell Lung Cancer (NSCLC) - innumerable small metastases detected on the Biograph Vision Quadra Total Body PET-CT Scanner, Angelique Brescia, Royal Prince Alfred Hospital			

## SATURDAY 14 May 2022 cont..

# 12:15 - 13:45 | Lunch - Plaza Ballroom 12:30 - 13:00 | Radiopharmaceutical Sciences SIG AGM 13:00 - 13:30 | GE Educational Session (Sponsor session) Plaza Auditorium The future of Paediatric Imaging with digital PET digital SPECT CT Chair: Kevin London – Westmead Children's hospital

13:45 | Poster walk and GMS Poster Award Judging - Plaza Ballroom & Foyer

:45 Concurrent Sessions 2A - 2D										
2A Technologists' Symposium 2 · Curium Award* Chair: Cristina Blefari and Suzanne McGavin			2B Oncology Chair: Maddison Carroll and John Barlow				posium 1	2D AANMS Symposium Chair: Dr Geoff Schembri and Dr Nicole Maggacis		
Plaza Auditorium	Pape #		Plaza P6	Pape #	r		Plaza P7	٨	Plaza P8	
			Proudly Sponsored By:				Proudly Sponsored By: UNITED UNITED		Proudly Sponsored By:	
14:00 The Utility of 18F-FET PET/MRI for the Differentiation of Post Therapy Changes vs Disease Recurrence in Brain Malignancy., Loren Katchel, Princess Alexandra Hospital *		028	14:00 Reprojected planar images derived from Lu- 177 Octreotate SPECT data – a suitable alternative to traditional planar imaging in peptide receptor radionuclide therapy?, Si Chen, Royal North Shore Hospital	29	031	14:00	Fully automated, commercial cassette-based production of high-purity [64Cu]CuCl2 from solid Ni target, Mario Malinconico, Comecer S.p.a.		14:00 Patient Selection and Imaging Biomarkers for PSMA Theranostics Michael Hofman, Peter MacCallum Cancer Centre	
H4:15 MRP Fusion using Hybrid Technology, Richard Boytar, Princess Alexandra Hospital	53	029			032	14:15	Scatter Fraction in Gallium-68 PET, Benjamin Crouch, South Australia Medical Imaging / Royal Adelaide Hospital Department Of Nuclear Medicine, PET and Bone Densitometry		14:20 Aspects of Alpha PRRT in NEN Aviral Singh, Genesis Care - Theranostics (Oncology)	
<sup>14:30</sup> TSIG Committee Overview Karen Jones, Chair TSIG Committee	97	030	imaging in assessing liver function pre and post		033	14:30	Imaging epigenetics: Synthesis and biological evaluation of a fluorine-18 bromodomain and extra-terminal inhibitor-based PET radiotracer, Catherine Fitzgerald, University Of Melbourne			
	logists' Symposium 2 rd*         rab Blefari and Suzanne McGavin         Plaza Auditorium         14:00         The Utility of 18F-FET PET/MRI for the Differentiation of Post Therapy Changes vs Disease Recurrence in Brain Malignancy., Loren Katchel, Princess Alexandra Hospital *         14:15       MRP Fusion using Hybrid Technology, Richard Boytar, Princess Alexandra Hospital         14:30       TSIG Committee Overview	logists' Symposium 2 rd*       28         rd*       28         rd*       28         Plaza Auditorium       ****         14:00       The Utility of 18F-FET PET/MRI for the Differentiation of Post Therapy Changes vs Disease Recurrence in Brain Malignancy., Loren Katchel, Princess Alexandra Hospital       **         14:15       MRP Fusion using Hybrid Technology, Richard Boytar, Princess Alexandra Hospital       *3         14:30       TSIG Committee Overview       \$7	Iogists' Symposium 2 rd* an Blefari and Suzanne McGavin     2B Onco Chair: Ma       Plaza Auditorium     Plaza Auditorium       14400 The Utility of 18F-FET PET/MRI for the Differentiation of Post Therapy Changes vs Disease Recurrence in Brain Malignancy, Loren Katchel, Princess Alexandra Hospital *     76     028       14415 MRP Fusion using Hybrid Technology, Richard Boytar, Princess Alexandra Hospital     53     029       14430 TSIG Committee Overview     97     030	Iogists' Symposium 2 rd*       28 Oncology         na Biefari and Suzanne McGavin       Chair: Maddison Carroll and John Barlow         Plaza Auditorium       Proudly Sponsored By:         Proudly Sponsored By:       Image: Chair: Maddison Carroll and John Barlow         Proudly Sponsored By:       Image: Chair: Maddison Carroll and John Barlow         Proudly Sponsored By:       Image: Chair: Maddison Carroll and John Barlow         Proudly Sponsored By:       Image: Chair: Maddison Carroll and John Barlow         Differentiation of Post Therapy Changes vs Disease Recurrence in Brain Malignancy., Loren Katchel, Princess Alexandra Hospital *       76       O28       14:00       Reprojected planar images derived from Lu- 177 Octreotate SPECT data – a suitable alternative to traditional planar imaging in peptide receptor radionuclide therapy?, Si Chen, Royal North Shore Hospital         14:15       MRP Fusion using Hybrid Technology, Richard Boytar, Princess Alexandra Hospital       53       029       14:15       Single-centre experience of treating men with metastatic castration-resistant prostate cancer with Lutetium-177 PSMA-I&T using TheraP-like treatment algorithm, Elizabeth Medhurst, Peter MacCallum Cancer Centre         14:30       TSIG Committee       97       030       14:30       The effectiveness of [99mTc]-Mebrofenin imaging in assessing liver function pre and post v-90 SIR-Spheres therapy, Nathaniel Tso, Royal	Iogists' Symposium 2 rd* aa Blefari and Suzanne McGavin       2B Oncology       2C         Chair: Maddison Carroll and John Barlow       Chair: Maddison Carroll and John Barlow       Sc         Plaza Auditorium       Plaza P6       Proudly Sponsored By:       Disease Recurrence in Brain Malignancy., Loren Katchel, Princess Alexandra Hospital *       76       028       14:00       Reprojected planar images derived from Lu- 177 Octreotate SPECT data – a suitable alternative to traditional planar imaging in peptide receptor radionuclide therapy?, Si Chen, Royal North Shore Hospital       29         14:15       MRP Fusion using Hybrid Technology, Richard Boytar, Princess Alexandra Hospital       53       029       14:15       Single-centre experience of treating men with metastatic castration-resistant prostate cancer with Lutetium-177 PSMA-I&T using TheraP-like treatment algorithm, Elizabeth Medhurst, Peter MacCallum Cancer Centre       54         14:430       TSIG Committee       97       030       14:30       The effectiveness of 199mTcJ-Mebrofenin imaging in assessing liver function pre and post Y-90 SIR-Spheres therapy, Nathaniel Tso, Royal       64	Iogists' Symposium 2 rd* aa Biefari and Suzanne McGavin       28 Oncology       2C Physic Sciences Chair: Maddison Carroll and John Barlow       2C Physic Sciences Chair: Dart Proudly Sponsored By:       20 BAGY ER         14:00       The Utility of 18F-FET PET/MRI for the Differentiation of Post Therapy Changes vs Disease Recurrence in Brain Malignancy., Loren Katchel, Princess Alexandra Hospital       76       028       14:00       Reprojected planar images derived from Lu- 177 Octroatate SPECT data – a suitable alternative to traditional planar imaging in peptide receptor radionuclide therapy?, Si Chen, Royal North Shore Hospital       29       031         14:15       MRP Fusion using Hybrid Technology, Richard Boytar, Princess Alexandra Hospital       53       029       14:15       Single-centre experience of treating me with metastatic castration-resistant prostate cancer with Lutetium-177 PSMA-I&T using TheraP-like treatment algorithm, Elizabeth Medhurst, Peter MacCallum Cancer Centre       151       032         14:430       TSIG Committee       97       030       14:30       The effectiveness of [99mTc]-Mebrofenin imaging in assessing liver function pre and post Y-90 SIR-Spheres therapy, Nathaniel Tso, Royal       64       033	Iogists' Symposium 2 rd* na Blefari and Suzanne McGavin       2B Oncology Chair: Maddison Carroll and John Barlow       2C Physics Sym Sciences Sym (Chair: Damion S Plaza Auditorium         Plaza Auditorium       Plaza Auditorium       Plaza P6       Proudy Sponsored By: Disease Recurrence in Brain Malignancy., Loren Katchel, Princess Alexandra Hospital *       Proudy Sponsored By: Disease Recurrence in Brain Malignancy., Loren Katchel, Princess Alexandra Hospital *       Prouge Spectro Control Content Contrecontrol Control Control Control Control Cont	Iogists' Symposium 2 rd*       28 Oncology       2C Physics Symposium 2 / Radiopharmaceutical Sciences Symposium 1 // Chair: Damion Stimson and Graeme O'Keefe         Plaza Auditorium       Plaza Auditorium       Plaza P6       Plaza P6       Plaza P7         Proudly Sponsored By:       Proudly Sponsored By:       Plaza P6       Proudly Sponsored By:       Plaza P7         U4:00       The Utility of 18F-FET PET/MRI for the Differentiation of Post Therapy Changes vs Disease Recurrence in Brain Malignancy., Loren Katchel, Princess Alexandra Hospital *       76       028       14:00       Reprojected planar images derived from Lu- 177 Octreotate SPECT data – a suitable alternative to traditional planar imaging in peptide receptor radionuclide therapy?, Si Chen, Royal North Shore Hospital       29       031       14:00       Fully automated, commercial cassette-based production of high-purity [64Cu]CuCl2 from solid Ni target, Mario Malinconico, Comecer S.p.a.         14:15       MRP Fusion using Hybrid Technology, Richard Boytar, Princess Alexandra Hospital       33       029       14:15       Single-centre experience of treating men with treatment algorithm, Elizabeth Medhurst, Peter MacCallum Cancer Centre       151       032       14:15       Scatter Fraction in Gallium-68 PET, Benjamin Crouch, South Australia Medical Imaging / Royal Adelaide Hospital Department Of Nuclear Medicine, PET and Bone Densitometry         14:430       TSIG Committee       97       030       14:30       The effectiveness of 199mTc]-Mebrofenin imaging in assessing liver function pre adpo	Jogists' Symposium 2 rd* na Blefari and Suzanne McGavin       28 Oncology (hair: Daries Symposium 2 / Radiopharmaceutical Sciences Symposium 1 (hair: Daries Symposium 2 / Radiopharmaceutical Sciences	

N	BA Technologists' Symposium 3 NM Undergraduate Student Award*		3B Cardiology /Respiratory					Neur				3D National Imaging Facility: Molecular Imaging and Radiochemistry Showcase					
Cha	air: Em		ook and Patrick Doggett	Chair: Joseph Wong and Stuart Ramsay					Chair: Paul Thomas and Evyn Arnfield					Chair: Prof Wojtek Goscinski			
per #	r		Plaza Auditorium	Paper #			Plaza P6	Paper #	r		Plaza P7			Plaza P8			
											Proudly Sponsored By: UNITED			Proudly Sponsored by: Australian Inputtion Contained Inputtion of Industry, Science, Except and Insurement In			
9	034		The role of 99mTc-Heat damaged red blood cell imaging in 68Ga-DOTATATE avid lesions: A case study,Mitchell Burton, University Of Newcastle *	81	038	15:1	<sup>5</sup> (VIRTUAL) The rate of cases in Auckland, New Zealand who have undergone both 99mTc-DPD scintigraphy as well as endomyocardial biopsy in order to diagnose transthyretin cardiac amyloidosis. , Zaineb Ukra, Auckland District Health Board	123	042	15:1	<sup>5</sup> The effect of fasting ketosis on brain FDG uptake in children and adolescents., Claire Eland, Rch Melbourne		15:15	<sup>5</sup> Introduction to NIF Radiochemistry Showcase Prof Wojtek Goscinski, National Imaging Facili			
47	035		The Functionality of 18-kda Translocator Protein Radioligand (18F)GE-180 as a Biomarker in the Diagnostic and Prognostic Evaluation of Spinal Cord Injury Imaging, Sunyu Cha, Benson Radiology *	122	O39	15:3	<sup>0</sup> Danger of using TC99m-HDP to exclude the ATTR form of Cardiac Amyloid, Dinesh Sivaratnam, The Royal Melbourne Hospital	132	043	15:3	<sup>0</sup> A prospective, multi-centre trial of FET-PET In Giloblastoma patients - the TROG 18.06 FIG Study: results of the Nuclear Medicine and Radiation Oncology credentialing program, Andrew Scott, Austin Health, Onjcri			<sup>10</sup> (LIVE ZOOM) Total Body PET Prof Steven Meikle, University of Sydney <sup>10</sup> Radiochemistry activities in Western Australia A/Prof Roslyn Francis, Sir Charles Gairdner Hospital and University of Western Australia			
33	036		Effect of the short-acting GLP-1 agonist, lixisenatide, on markers of inflammation and oxidative stress in health and type 2 diabetes, Assunta Lepore, University of South Australia *	10	O40	15:4	<sup>5</sup> Comparison between viral vector and mRNA based COVID-19 vaccination in prevalence and severity of regional immune reactions, and 18F- FDG PET/CT features, Narjess Ayati, Westmead Hospital	143	044	15:4	<sup>5</sup> Immuno-PET agents for Targeting Glioblastom , Saikat Ghosh, The University Of Queensland	a		<sup>6</sup> Australian Precision Medicine Enterprise Prof Gary Egan, Monash Biomedical Imaging and ARC Centre of Excellence for Integrative Brain Function			
														<sup>60</sup> Alpha therapies and activities Prof Kristofer Theurecht, University of Queensland and Australian Institute for Bioengineering and Nanotechnology			
19	037		A comparative review into the effectiveness of 18F-FDG PET/CT and MRI in diagnosing solitary plasmacytomas, Victoria Neale, University of South Australia *	44	041	16:0	<sup>0</sup> Is the ventilation scan important in V/Q scan with low dose CT in patients with active COVID- 19 infection and suspected pulmonary embolism?, Stella Jo, Royal Adelaide Hospital	70	045	16:0	<sup>0</sup> Pre-Clinical Evaluation of First PET Probe For Ir Vivo Imaging of Brain Endocannabinoid α/β- Hydrolase Domain 6 (ABHD6), Muneer Ahamed, SAHMRI, Adelaide	1	16:0	<sup>∞</sup> ANSTO's new NIF Alpha Radioisotopes and Radiopharmaceuticals Facility Dr John Bennett, ANSTO			

# 16:15 - 17:00 PLENARY - Plaza Auditorium

16:15 | **Lowenthal Lecture:** Chair: James Turner

(LIVE ZOOM) PET-based radiomics for personalised medicine, Professor Kenneth Miles 17:00 | Close

## 19:00: ANZSNM ASM 2022 Awards Dinner Brisbane Convention & Exhibition Centre

Plaza Terrace Room

Proudly Sponsored by: ANSTO



07: 07:	30 - 3 30	.3:00 Regi	ibition and Poster Displays Open - Plaza Ba 10   Speaker Support - Concord Speaker Pre istration - Plaza Ballroom Foyer laza Auditorium		oyer									
)8: Cha Brii The	20   F ir: Sa ging PET	e Tir PET Jour	Icome Day 2 Iary 3: Celebrating 30 Years of PET in Austr ing Lee T to Australia – the Long and Winding Roa Irney – Trials, Evidence and Approval, Prof PET: where are we now? An era of innova	<b>d</b> , Prof. Dale . Andrew Sc	ott, A	ustin	Health, and Olivia Newton-			tal		Proudly Sponsored by: SIEMENS Healthineers	>	
9:5	0   N	lorni	ning Tea and Poster Viewing - Plaza Ballroom											
10:	L5	Pion	laza Auditorium neer Lecture: ajane Michel											
Obs	erva	nces	s of Progress over 40 Years, Anne McClena											
			2:30   Concurrent Sessions 4A -	4D	40	<b>T</b>		- the state of the	40	- False		and New Horizons		RTnet
ŧA	Unc	olog	ВУ		4В			echnology	40	. Eauc	atior	and New Horizons	4D AF	kinet
Cha	ir: B	ittar	iny Robinson and Catherine Lucas		Cha	ir: Joh	n Blazak and James Turner		Ch	air: Sa	rah D	aniel and Tess Smith	Chair:	Bridget Chappell
g .			Plaza Auditorium Proudly Sponsored By: CANON MEDICA		aper		Plaza P6 Proudly Sponsored by:	TELIX	a a a a a a a a a a a a a a a a a a a			Plaza P7 Proudly Sponsored by: Autorbit Covernment Radioactive		Plaza P8
24	046	1	11:00 The value of FDG PET/CT imaging in o prediction and response assessment o lymphoma patients treated with immunotherapy: a meta-analysis and systematic review, Narjess Ayati, Wes Hospital	of	140	052	11:00 New 64Cu-labeled C theranostic applicati University Of Queen	ions , Vanessa Soh,	21	058	11:	<sup>20</sup> Concurrent measurement of serum and radiomic biomarkers in the clinical investigation of equine musculoskeletal injuries: A pilot study., Pete Tually, Telemed		11:00 Welcome and ARTnet overview A/Prof Roslyn Francis, Scientific Chair, ARTn Prof Karen Jones, Executive Chair, ARTnet
78	047	1	11:15 (VIRTUAL) Quadra Total Body PET-CT prostate cancer with 68Ga-PSMA , Em Caddey, Rpah		31	053		targeted alpha therapy 595 for pancreatic cancer, sity of South Australia	57	059	11:	<sup>15</sup> Rethinking Radiation safety advice to hospita non-radiation workers: Complications arising from conservative guidelines, Enid Eslick, St Vincent's Hospital, Sydney		11:20 Prostate cancer trials Prof Michael Hofman, Peter MacCallum Ca Centre
121	048	1	11:30 Prognostic impact of combined FDG P somatostatin receptor PET scans in th prognosis of Neuroendocrine tumours Choudhury, Tata Memorial Hospital, N	ie s, Sayak	152	054	11:30 Engineering a PSMA accelerated clearanc tumour accumulatio University Of Queen	e while maintaining n , Nicholas Fletcher, The	88	060	11:	<sup>30</sup> State of the profession: workforce demands f Nuclear Medicine Technologists, Daphne James, University Of Newcastle	or	11:40 FIG study / iFIRST study Prof Andrew Scott, Olivia Newton-John Can Research Institute
136	049	1	11:45 The utility of 99mTc-pertechnetate sc scan in predicting post radioactive iod ablation breast uptake in postpartum Alexander Berry, Northern Sydney Loc District	line patients,	63	055	11:45 Solving the demand 212Pb for Targeted / Simon Puttick, Advar	Alpha Therapy,	67	061	11:	<sup>15</sup> The Effectiveness of an Alternative Learning Package for First-Year Nuclear Medicine Students, Melissa Shields, The University Of Newcastle		12:00 XSPECT projects Dr Stuart Ramsay, Royal Brisbane Hospital
22	050	1	12:00 Peritoneal lymphomatosis in recurren follicular lymphoma on 18F-FDG PET/ Wai Chung Wong, Queen Elizabeth Ho	CT,	58	056	primary hepatic mal	in paediatric patients with ignancy: An Australian ises., Karan Singh, The it Westmead	106	062	12:0	O A considered approach to preparing for student placements, Suzanne McGavin, Rmit Univeristy		12:10 Future opportunities A/Prof Roslyn Francis, Scientific Chair, ARTr
27	051	1	<sup>12:15</sup> A Case of Transformed Mycosis Fungo Lisa MacFarlane, Peter Maccallum Car Centre		118	057	12:15 PSMA screening phe personalisation of ra recommendations., Hospital, Sydney							12:20 Open discussion
			ZSNM AGM - Plaza Auditorium ch and Poster Viewing - Plaza Ballroom & F	oyer										
			ENARY - Plaza Auditorium									1		
Cha ( <b>LIV</b> Uni	ir: D 'E ZC v-Pro	r Sta OM of. Di	iary 4: anley Ngai 1) FAP-ligand: new perspective in cancer si 70. Frederik Giesel, MD, MBA, Heinrich Hein ference Highlights									Proudly Sponsored by:	S	

Poste	er Pre	esentations									
		GMS Poster Award Nominees * NM Undergraduate Student Award**									
98	P1	POSTERS PET Findings in Sars-CoV-2 Vaccinated Oncology Patients, Marney Greenwood, Austin Health *	62	P11	POSTERS [68Ga]Ga-PSMA: An evaluation between the direct elution and pre-concentration method using dual Eckert & Ziegler 68Ge/68Ga generators on the iPhase MultiSyn radiosynthesiser, Uwe Ackermann, Austin Health	75	P21	POSTERS Optimising Nuclear Medicine and PET Diagnostic Reference Levels (DRLs), Nick Wright, Austin Health *	4 61	P31	POSTERS Accuracy and sensitivity of 18F-PSMA PET/CT versus 11C-choline PET/CT in the evaluation of prostate cancer patients with suspected recurrence Mathuri Sakthithasan, Bristol Royal Infirmary
107	P2	Establishing [18F]FDGalactose as a PET Tracer for Research Imaging, Christoph Barkhausen, National Imaging Facility	95	P12	Sequential PET/MRI and PET/CT imaging in prostate cancer: The Princess Alexandra Hospital Experience, Emma Brook, Princess Alexandra Hospital *	90	P22	Establishing the Radiopharmaceutical [11C]C- PIB as "Ready-to-Use" in Humans at the CAI, Christoph Barkhausen, National Imaging Facility	65	P32	Equivocal Radiotracer Uptake on 18F-PSMA- 1007 PET/CT in Patients with Prostate Cancer, Mathuri Sakthithasan, Bristol Royal Infirmary
154	P3	Hepatobiliary scintigraphy post Whipple procedure: A case study, Kate Romeo, Sir Charles Gairdner Hospital *	141	P13	The value of 18-FDG PET in the treatment response and management of fungaemia., Alanah Incantalupo, Austin Health	38	P23	The Role Of Nuclear Medicine Theranostics In A Patient Diagnosed With A Large Cholangiocarcinoma Unable To Be Treated By Chemotherapy - A Case Study , Naomi Kelada, Rmit **	66	P33	Cushing's syndrome secondary to an ACTH- producing neuroendocrine tumour of the maxillary sinus, Mathuri Sakthithasan, Bristol And Weston University Hospitals - Nhs England
116	P4	Glioblastoma - [18F]DCFPyL avid tumour? , Edward Yeoh, St Vincent's Hospital Melbourne/Monash Health	150	P14	(VIRTUAL) PET saves the day with hearty diet preparation, Emma Harding, Austin Health	117	P24	18F-FDG PET/CT in Post-Covid-19 Lung Disease (PCLD) in poor outcome patients: A case series, Yogita Khandelwal, Sanjay Gandhi Post Graduate Institute Of Nuclear Medicine	130	P34	Comparative effects of low-carbohydrate, full- strength and low-alcohol beer on gastric emptying, alcohol absorption, glycaemia and insulinaemia in health., Karen Jones, University of Adelaide
42	P5	A rare variant of migraine with brainstem aura, diagnosed with rest and stress cerebral perfusion SPECT studies, Mark Dobson, Bankstown Lidcombe Hospital	108	P15	Occupational radiation exposure of Nuclear Medicine Advanced Trainees at the Wollongong Hospital: a thirteen-year audit., Elizabeth Clingan, Wollongong Hospital	134	P25	The effect of eight weeks' treatment with the short-acting GLP-1 agonist, lixisenatide, on postprandial blood pressure and heart rate in patients with type two diabetes – A secondary quantitative study., Alan Lu, University Of South Australia **	69	P35	Detection rates at different PSA levels and positive predictive value of 18F-PSMA PET/CT in the evaluation of prostate cancer patients with suspected recurrence., Mathuri Sakthithasan, Bristol Royal Infirmary
146	P6	The usefulness of PET in assessing a rare Neuroendocrine tumour of the thymus, Rebecca Wyborn, (The) Princess Alexandra Hospital	153	P16	Developing thiosemicarbazone and semicarbazone radiocomplexes for applications in diagnostic and nuclear medicine, Brett Paterson, Centre For Advanced Imaging	155	P26	The utility of 68GaPSMA expression in Adenoid Cystic Carcinoma of the head and neck: A case study, Anisa Kumari, Princess Alexandra Hospital	80	P36	Not So Specific Membrane Antigen-A 68Ga- PSMA Case Study, Brittany Robinson, Royal Brisbane And Womens Hospital *
51	P7	Development of High Performance Liquid Chromatography (HPLC) Quality Control Method for evaluation of 18F-fluoro- dihydrotestosterone (18F-FDHT), an androgen receptor PET imaging ligand, Kenneth Young, Austin Health	127	P17	Comparison of whole body bone scan (WBS) alone versus together with either single region Single Photon Emission Tomography (SPECT)/Computerised Tomography (CT) or 2+ region SPECT/CT in oncological staging., Andrew Tauro, Austin Health	83	P27	Going 'Ga-Ga' over 68-Gallium-Citrate; is this the Latest and Greatest Solution to Imaging Osteomyelitis?, Emma Samie, University Of South Australia **	82	P37	Short data acquisition for an obese patient (190kg) on the Biograph Vision Quadra Total Body PET-CT Scanner, Alexis Hughes, Royal Prince Alfred Hospital
48	P8	Design of High-Resolution Brain PET Using Dual- Layer DOI Detector , Wonsuk Lim, Sogang University		P18	Quantification and SUVs in SPECT/CT studies , Tess Smith, SAMI - The Queen Elizabeth Hospital	52	P28	Pulmonary/Cardiac Sarcoidosis 18F FDG PET: A Case Study , Holly Spooner, University Of Newcastle **	86	P38	Impact of PET reconstruction parameters on the quantitation of longitudinal PET $A\beta$ -amyloid, Gihan Ruwanpathirana, University of Melbourne
71	P9	Cardiac PET/MRI: Unleashing an Emerging Imaging Technique , James Turner, Princess Alexandra Hospital, Queensland Health *	87	P19	PSMA PET/MRI in initial staging and local recurrence: a pictorial review, Nikki Weinert, Qld Health	8	P29	(VIRTUAL) Radiochemical Stability of therapeutic radiopharmaceutical of 177Lu- PSMA I&T, Rudresh Chandrashekar, Mercy Radiology *	60	P39	Radioactive recoveries following clinical production of 2-Deoxy-2-[18F]fluoroglucose ([18F]FDG) using Synthera synthesizers, Uwe Ackermann, Austin Health *
144	P10	18F-FDOPA PET/MRI imaging to distinguish patients with early Parkinson's Disease vs atypical Parkinsonism, Emma Brook, Princess Alexandra Hospital *	139	P20	Incidental detection of a Baker's (Popliteal) cyst on Ga- 68 PSMA PET/CT, Trent Cook, Nepean Hospital Nuclear Medicine And Pet Dept. *	68	P30	Phase I dose escalation trial of PSMA Targeted Alpha Therapy using 212Pb in Metastatic Hormone Refractory Prostate Adenocarcinoma, Stephen Rose, AdvanCell Isotopes	124	P40	The Utility of 18F–FDG PET/MR Imaging in Patients with Aortitis – 'The Writing is on the Vessel Wall', Loren Katchel, Princess Alexandra Hospital *

## Poster Presentations cont..

		GMS Poster Award Nominees * NM Undergraduate Student Award**									
aper #		POSTERS	Paper # 110		POSTERS	Paper #		POSTERS	Paper #		POSTERS
42	P41	The contribution of nuclear medicine in a multimodality approach to identify the unclear cause of an aortic arch intramural haematoma – a case study, Emma Carrington, SCUH	110	P51	"There's been a change of plans" – Nuclear Medicine's role in helping change the clinical pathway of a patient when incidental findings arise during staging, Sarah Stephenson, South Australia Medical Imaging (SAMI) - Royal Adelaide Hospital *	34	P61	Evaluating outcomes of NEN managed by high dose radiations., Arooj Fatima, Sir Gangaram Hospital	131	P71	Measurement of gastric emptying using a 130 octanoic acid breath test with Wagner-Nelso analysis and scintigraphy in type 2 diabetes., Karen Jones, University of Adelaide
84	P42	Optimised production and quality control of Lutetium-177 PSMA I&T with an automated radiosynthesizer: Westmead Hospital experience., Catherine Au, Westmead Hospital	101	P52	A clinical pathway for differentiating parkinsonian syndromes and Parkinson's disease using dual tracer Fluorine-18 Fluorodopa and Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography / Computed Tomography, Emma Carrington, SCUH	35	P62	Analysing the effectiveness Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. A Journey towards optimising the treatment options for NET., Arooj Fatima, Sir Gangaram Hospital	73	P72	A multi-centric approach to hepatopulmonan syndrome during the coronavirus pandemic, Randeep Kulshrestha, University Hospitals Of Bristol & Weston Nhs Foundation Trust
92	P43	Low Activity Reconstruction of Philips PET Scans, Graeme O'keefe, Austin Health	45	P53	External Beam Radiotherapy in Combination with Theranostic Radiologand Therapy for Oligometastatic Prostate Cancer (ProstACT- TARGET), Nat Lenzo, GenesisCare Oncology	39	P63	(VIRTUAL) Describing and quantifying 68Ga- nitroimidazole uptake in tuberculosis hypoxia: a proof-of-concept study, Philippa Bresser, University Of Auckland	135	P73	Pleuroperitoneal Fistula in Peritoneal Dialysis, Shoba Ratnagobal, Sir Charles Gairdner Hospi
54	P44	Combining Individual and Model-Based Internal Dosimetry Calculation for Radionuclide Therapy using MrVoxel/OCD, Erin Mckay, South Eastern Sydney Local Health District *	12	P54	Dacroscintigraphy: Normative Quantitative Values and Effect of Lid Massage., Chong Chew, Royal Adelaide Hospital	91	P64	EPIC-Skin study will Evaluate Efficacy of Rhenium-Skin Cancer Therapy (SCT) for the treatment of non-melanoma skin cancer., Saima Vohra, Oncobeta Therapeutics			
59	P45	Rhabdomyolysis seen on bone scintigraphy, Rahul Solanki, South Australian Medical Imaging	114	P55	Validation of the quantitative global Centiloid unit using MIMNeuro <sup>®</sup> to assess beta amyloid (Aβ) detection in [18F]-Florbetaben PE, Kye Tull, Royal North Shore Hospital	96	P65	68Ge/68Ga Generator Use in Clinical Productions: Effect of Elution Frequency, Cassandra Fulcher, Qld Health			
115	P46	A Case of Renal Cortical Necrosis on DMSA SPECT/CT, Edward Yeoh, St Vincent's Hospital Melbourne/Monash Health	15	P56	Incremental Utility of 68Ga-PSMA PET/CT in staging and response assessment of osteolytic skeletal lesions in prostate cancer, Surekha Yadav, Army Hospital Research And Referral	99	P66	Added value of multiphase thin slice CT in 4D- SPECT/CT 99mTc-sestamibi imaging in patients with primary hyperparathyroidism: a precision guided tool for the surgeons, Randeep Kulshrestha, University Hospitals Of Bristol & Weston Nhs Foundation Trust			
113	P47	Case of large-vessel vasculitis following Comirnaty (Pfizer) COVID-19 vaccination. Confirmed with 18F-FDG PET/CT., Adam Sennett, I-med Radiology - Wagga Wagga	16	P57	Multiple Myeloma masquerading as Seronegative Polyarthritis: Case series and Review of literature to evaluate the Utility of 18F-FDG PET/CT , Surekha Yadav, Army Hospital Research And Referral	109	P67	Building a Radiopharmacy: The Cost of GMP, Shannon Millar, QTRACE, Dept. Nuclear Medicine and PET services, Royal Brisbane and Womens Hospital			
147	P48	Change in diagnosis and incidental findings on low-dose CT during SPECT/CT Sestamibi cardiac nuclear medicine studies, Rosalie Babicheva, Bankstown/lidcombe Hospital	17	P58	18F-FDG PET/CT in staging, restaging and detecting recurrence in Paediatric and AdolescentEwing Sarcoma: A potential Prognostic Tool, Surekha Yadav, Army Hospital Research And Referral	111	P68	Optimising the Synthesis and QC of [177Lu]Lu- PSMA I&T for Prostate Cancer Therapy, Kenneth Kam Chung Hong, Prince of Wales Hospital			
120	P49	Bertolotti's syndrome and bone scan underutilisation., Patrick Doggett, Noosa Radiology	18	P59	A Review of literature and Role of Molecular Imaging in Congenital hypothyroidism: Where do we fit in?, Surekha Yadav, Army Hospital Research And Referral	112	P69	Automated radiopharmaceutical dispensing: challenges, risks, and improvements, Nick Aslin, Q-trace			
138	P50	Radiation Induced Osteitis of the Mandible Imaged by FDG-PET and 99mTc-Sestamibi , Vincent Hoang, Nepean Hospital Nuclear Medicine And Pet Dept. *	23	P60	Diagnosis of phaeochromocytoma from FDG- PET in a patient with reverse Takotsubo cardiomyopathy., Michelle Nottage, Royal Adelaide Hospital	129	P70	Utility and cost effectiveness of a 3D printer in a Nuclear Medicine Department., Matthew Griffiths, Ph.D, Nuclear Medicine Royal Brisbane And Women's Hopsital			